Official ESCRS | European Society of Cataract & Refractive Surgeons
Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance

Take a look inside the London 2014 Congress


Then register to join us
in Barcelona!


Search Abstracts by author or title
(results will display both Free Papers & Poster)

Results of single-stage cataract phacoemulsification and canaloplasty in patients with glaucoma

Poster Details

First Author: I.Khusnitdinov RUSSIA

Co Author(s):    M. Bikbov                    

Abstract Details


To analyze the results of single-stage cataract phacoemulsification with IOL implantation and canaloplasty using Glaucolight system in patients with primary open-angle glaucoma (POAG).


Ufa Eye Research Institute, Ufa, Russia


We observed 29 patients (29 eyes) who underwent combined phacoemulsification of complicated cataract with IOL implantation and canaloplasty with Glaucolight for POAG. Mean age of patients was 55.2±5.9 years, average preoperative IOP rate – 33.5±4.1 mm Hg. Observations were conducted during 12 months. Initial stage of POAG occurred in 17 cases, developed – in 9, advanced – in 3. None of the patients had antiglaocomatous surgeries before.


After the surgery and in 12 months IOP averaged 13,1±2,4 and 15,5±2,1 mm Hg respectively. After canaloplasty microhyphema was observed in 14 patients but it resolved in 1-5 days. Complications: Schlemm’s canal perforation and migration of catheter into suprachoroidal spacу with a hemorrhage into anterior chamber. In two cases there was a Schlemm’s canal obstruction that is more common in patients with advanced stage of glaucoma. Visual acuity increased in all patients and varied from 0.1 to 1.0. in two cases IOP increased in 1 month after the surgery. Gonipuncture to the Descemet’s window was conducted.


Single-stage surgical treatment of cataract and open-ange glaucoma using phacoemulsification+IOL and canaloplasty with Glaucolight is an effective and safe surgery contributing to drop of IOP and improvement of visual acuity.

Financial Disclosure:


Financial Disclosure:


Back to Poster listing